In our study, we show that pediatric cancer tumor types other than Ewing’s sarcoma also demonstrate sensitivity to PARP inhibition, independent of STAG2 mutation or EWS-FLI1 fusion. The gene discussed is PARP1; the disease is Ewing sarcoma.